Background information and treatment recommendations for patients with HIV/AIDS

American Journal of Psychiatry

Volumn 157, Issue 11 SUPPL., 2000, Pages 1-62

  Atkinson, J ^a   Batki, S ^a   Beaudin, C L ^a   Bell, C ^a   Bennett, M ^a   Berkman, A ^a   Bialer, P A ^a   Blackinton, C H ^a   Blaustein, M ^a   Brady, M T ^a   Breitbart, W ^a   Broadbent, R ^a   Cabaj, R P ^a   Chuck, S ^a   Clemens, N A ^a   Davis, D ^a   Epstein, S A ^a   Feingold, A ^a   Ferrando, S ^a   Gorman, J ^a   Greenberg, W M ^a   Haikalis, S ^a   Halman, M ^a   Hartmann, L ^a   Hendrickson, R M ^a   Herzog, A ^a   Hicks, D ^a   Horwath, E ^a   Hughes, M ^a   Janofsky, J S ^a   Jones, T S ^a   Juthani, N V ^a   Kobayashi, J ^a   Kennedy, C A ^a   Kertzner, R ^a   Kline, L Y ^a   Koegler, R R ^a   Kosten, T ^a   Labins, Z ^a   Lyon, D E ^a   Markowitz, J C ^a   McCance Katz, E F ^a   McKinnon, K ^a   Muskin, P R ^a   Rabkin, J ^a   Rosmarin, D ^a   Ross, P ^a   Ruiz, P ^a   Siegel, L ^a   Stasko, R ^a   Tatomer, W R ^a   Thornhill IV, J T ^a   Treisman, G J ^a   Wainberg, M L ^a   Warren, B ^a   Worth, J L ^a   Zilber, C ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIRETROVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; BUSPIRONE; CARBAMAZEPINE; CITALOPRAM; CYTOCHROME P450; DELAVIRDINE; DRONABINOL; EFAVIRENZ; FLUOXETINE; FLUVOXAMINE; GLUCOCORTICOID; HALOPERIDOL; INDINAVIR; LITHIUM; MIRTAZAPINE; NEFAZODONE; NELFINAVIR; NEUROLEPTIC AGENT; NEVIRAPINE; OXANDROLONE; PAROXETINE; PROTEINASE INHIBITOR; PSYCHOSTIMULANT AGENT; PSYCHOTROPIC AGENT; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; SAQUINAVIR; SERTRALINE; THALIDOMIDE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VENLAFAXINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; AFFECTIVE NEUROSIS; ALTERNATIVE MEDICINE; BONE MARROW TOXICITY; CENTRAL NERVOUS SYSTEM DEPRESSION; CLINICAL FEATURE; COMORBIDITY; DEPRESSION; DROWSINESS; EXTRAPYRAMIDAL SYMPTOM; GASTROINTESTINAL TOXICITY; HEALTH CARE ACCESS; HEART MUSCLE CONDUCTION DISTURBANCE; HIGH RISK PATIENT; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICOLEGAL ASPECT; MENTAL DISEASE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; REVIEW;

EID: 0033773812     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (473)

1. Viral counts count in HIV infection
2. Caring for people with human immunodeficiency virus infection
3. Slowing decline in AIDS deaths prompts concern
4. Prevention of HIV/AIDS and other blood-borne diseases among injection drug users: A national survey on the regulation of syringes and needles
5. Symptomatic primary infection due to human immunodeficiency virus type 1: Review of 31 cases
6. Sexual transmission and propagation of SIV and HIV in resting and activated CD4+ T cells
7. Early establishment of a pool of latently infected, resting CD4(+) T cells during primary HIV-1 infection
8. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy
9. HIV-1 RNA levels in cerebrospinal fluid and plasma correlate with AIDS dementia
10. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management
11. Monitoring plasma HIV-1 RNA levels in addition to CD4+ lymphocyte count improves assessment of antiretroviral therapeutic response
12. Changes in plasma HIV RNA levels and CD4+ lymphocyte counts predict both response to antiretroviral therapy and therapeutic failure
13. 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
14. Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy
15. HIV-1 protease inhibitors: A review for clinicians
16. HIV-1 drug resistance in newly infected individuals
17. Primary HIV-1 resistance: A new phase in the epidemic?
18. HIV-associated dementia: New insights into disease pathogenesis and therapeutic interventions
19. The neuropathogenesis of HIV-1 infection
20. The effects of human immunodeficiency virus in the central nervous system
21. Plasma viral load and CD4 lymphocytes predict HIV-associated dementia and sensory neuropathy
22. HIV-1 compartmentalization and discordant virologic failure in CSF and plasma
23. Discordant HIV-1 RNA decay in CSF versus plasma following initiation of antiretroviral therapy: A prospective ultra-intensive CSF sampling study
24. A national, randomized survey of HIV/AIDS attitudes and knowledge among psychiatrists-in-training
25. Early central nervous system response to HIV infection: Sleep distortion and cognitive-motor decrements
26. Cognition in early human immunodeficiency virus infection
27. Neuroleptic treatment of HIV-associated psychosis
28. Secondary mania in patients with HIV infection: Are antiretrovirals protective?
29. Secondary mania in patients with HIV infection
30. AIDS mania
31. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection report of a working group of the American Academy of Neurology AIDS Task Force
32. Pathogenesis of HIV-1 associated neurodegeneration
33. Mortality risks in gay men with human immunodeficiency virus infection and cognitive impairment
34. Neurocognitive impairment is an independent risk factor for death in HIV infection
35. Human immunodeficiency virus-associated dementia: Review pf pathogenesis, prophylaxis, and treatment studies of zidovudine therapy
36. Combination antiretroviral therapy improves psychomotor speed performance in HIV-seropositive homosexual men: Multicenter AIDS Cohort Study (MACS)
37. Changes to AIDS dementia complex in the era of highly active antiretroviral therapy
38. Psychosis associated with HIV infection
39. New-onset psychosis in HIV-infected patients
40. Psychiatric disorders in HIV-spectrum illness
41. Organic mental disorders in HIV-1 infection
42. A doubleblind trial of haloperidol, chlorpromazine, and Iorazepam in the treatment of delirium in hospitalized AIDS patients
43. Practice guideline for the treatment of patients with delirium
44. Identifying depression in the old old
45. Human immunodeficiency virus and AIDS
46. Severe mental illness and HIV-related medical and neuropsychiatric sequelae
47. Neuropsychiatric aspects of HIV infection and AIDS
48. Natural history of vertically acquired human immunodeficiency virus-1 infection
49. Acquired immunodeficiency syndrome and the developing nervous system
50. Neurological and developmental problems in pediatric HIV infection
51. Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection
52. Influence of family factors and illness parameters on HIV-infected children's cognitive, academic and psychological functioning
53. Adaptive behavior of children with symptomatic HIV infection before and after zidovudine therapy
54. Cognitive functioning in schoolage children with human immunodeficiency virus
55. Prevalence of psychiatric disorders among men infected with human immunodeficiency virus: A controlled study
56. Prevalence of psychiatric disorders in early stages of HIV infection
57. Multidisciplinary baseline assessment of homosexual men with and without human immunodeficiency virus infection, II: Standardized clinical assessment of current and lifetime psychopathology
58. An assessment of rates of psychiatric morbidity and functioning in HIV disease
59. Use of hospital services by AIDS patients with psychiatric illness
60. Depressive affect and survival among gay and bisexual men infected with HIV
61. Psychiatric morbidity on entry to an HIV primary care clinic
62. Psychopathology in male and female HIV-positive and negative injecting drug users: Longitudinal course over 3 years
63. Prevalence of axis I disorders in an AIDS cohort: A cross-sectional, controlled study
64. Psychopathology in human immunodeficiency virus infection: Lifetime and current assessment
65. Psychiatric diagnosis before serological testing for the human immunodeficiency virus
66. Mood disorders in HIV infection: Prevalence and risk factors in a nonepicenter of the AIDS epidemic
67. Psychopathology in male and female intravenous drug users with and without HIV infection
68. The relative contributions of psychiatric symptoms and AIDS knowledge to HIV risk behaviors among people with severe mental illness
69. Violence victimization after HIV infection in a US probability sample of adult patients in primary care
70. Addressing HIV infection in office practice: Assessing risk, counseling, and testing
71. HIV prevention case management: Current practice and future directions
72. Postexposure treatment of people exposed to the human immunodeficiency virus through sexual contact or injection-drug use
73. Public health service guidelines for the management of health-care worker exposures to HIV and recommendations for postexposure prophylaxis
74. Harm reduction: Concepts and practice: A policy discussion paper
75. Substance abuse and HIV
76. The protective effect of AIDS-related behavioral change among injection drug users: A cross-national study
77. HIV seroprevalence among people with severe mental illness in the United States: A critical review
78. Sexual activity and risk of HIV infection among patients with schizophrenia
79. HIV and people with serious mental illness: The public sector's role in reducing HIV risk and improving care
80. HIV among people with mental illness: Contributing factors, prevention needs, barriers, and strategies
81. Increasing assertiveness skills to reduce HIV risk among women living with a severe and persistent mental illness
82. HIV risk reduction interventions for persons with severe mental illness
83. Postexposure prophylaxis for human immunodeficiency virus (HIV) infection following sexual assault
84. Position statement on confidentiality, disclosure, and protection of others
85. Adherence to protease inhibitor therapy and outcomes in patients with HIV infection
86. Determinants of compliance with antiretroviral therapy in patients with human immunodeficiency virus: Prospective assessment with implications for enhancing compliance
87. Severity of psychiatric symptoms after HIV testing
88. The response of religious congregations to the spiritual needs of people living with HIV/AIDS
89. Guidelines for spiritual assessment
90. Communication of preferences for care among human immunodeficiency virus-infected patients: Barriers to informed decisions?
91. 'Mini-Mental State': A practical method for grading the cognitive state of patients for the clinician
92. A new bedside test of cognition for patients with HIV infection
93. HIV Dementia Scale: A rapid screening test
94. Bedside assessment of executive cognitive impairment: The Executive Interview
95. Validity of two scales in identifying HIV-associated dementia
96. Metacognition in HIV-1 seropositive asymptomatic individuals: Self-ratings versus objective neuropsychological performance
97. Outcomes associated with delirium in acutely hospitalized acquired immune deficiency syndrome patients
98. Association between delirium and death in AIDS patients
99. Somatic symptoms and HIV infection: Relationship to depressive symptoms and indicators of HIV disease
100. Didanosine-induced mania in HIV infection
101. Manic syndrome associated with zidovudine treatment
102. The effect of entering drug treatment on involvement in HIV-related risk behaviors
103. Practice guideline for treatment of patients with substance use disorders: Alcohol, cocaine, opioids
104. Psychiatric risk factors in HIV seropositive adolescents
105. Psychiatric morbidity in school-age children with congenital human immunodeficiency virus infection: A pilot study
106. The University of Minnesota Youth and AIDS Projects' Adolescent Early Intervention Program: A model to link HIV-seropositive youth with care
107. Long-term physical illness in childhood: A challenge to psychosocial adaptation
108. Psychological aspects of the management of chronic diseases and handicapping conditions in childhood
109. Magnitude of body cell mass depletion and the timing of death from wasting in AIDS
110. Fatigue in ambulatory AIDS patients
111. Fatigue in HIV illness: Relationship to depression, physical limitations, and disability
112. Fatigue in cancer and HIV/AIDS
113. Pain in ambulatory AIDS patients, 1: Pain characteristics and medical correlates
114. The experience of pain in persons with HIV/AIDS
115. Painful symptoms reported by ambulatory HIV-infected men in a longitudinal study
116. Testosterone therapy for human immunodeficiency virus-positive men with and without hypogonadism
117. HIV/AIDS among racial/ethnic minority men who have sex with men - United States
118. Sexual and drug-use risk factors for HIV and STDs: A comparison of women with and without bisexual experiences
119. HIV and AIDS relative to other health, social, and relationship concerns among low-income urban women: A brief report
120. Heterosexual transmission of human immunodeficiency virus (HIV) in northern California: Results from a ten-year study
121. Sex differences in HIV-1 viral load and progression to AIDS
122. A group approach to psychosocial issues faced by HIV-positive women
123. The difficulties of women living with HIV infection
124. HIV-related medical issues in older people
125. AIDS risk behaviors among late middle-aged and elderly Americans: The National AIDS Behavior Surveys
126. Prevalence of sexual and drug-related HIV risk behaviors in the US adult population: Results of the 1996 National Household Survey on Drug Abuse
127. Prevention strategies other than male condoms employed by low-income women to prevent HIV infection
128. Psychosocial predictors of life satisfaction among persons living with HIV infection and AIDS
129. Suicide risk in patients with human immune deficiency virus infection and acquired immune deficiency syndrome
130. Increased risk of suicide in persons with AIDS
131. AIDS and suicide in California
132. Risk of suicide among persons with AIDS: A national assessment
133. HIV seroprevalence among suicide victims in New York City, 1991-1993
134. Suicide among gay, lesbian, and bisexual persons: Current trends and opportunities for prevention
135. Suicide and HIV infection: Mortality follow-up of 4,147 HIV-seropositive military service applicants
136. Death from suicide and overdose among drug injectors after disclosure of first HIV test result
137. AIDS-related illness and AIDS risk in male homo/bisexual substance abusers: Case reports and clinical issues
138. Sexual versus psychiatric predictors of suicide in men with AIDS-related illnesses
139. Suicidal ideation, suicide attempts, and HIV infection
140. HIV disease and suicide
141. Suicide assessment and intervention with persons infected with HIV
142. HIV sexual risk behavior following bereavement in gay men
143. Suicidal ideation, bereavement, HIV serostatus and psychosocial variables in partners of men with AIDS
144. Effects of AIDS-related bereavement and HIV-related illness on psychological distress among gay men: A 7-year longitudinal study, 1985-1991
145. Unique patterns of bereavement in HIV: Implications for counselling
146. The impact of illness disclosure and custody plans on adolescents whose parents live with AIDS
147. Problem behavior of adolescents whose parents are living with AIDS
148. Bereavement reactions among homosexual men experiencing multiple losses in the AIDS epidemic
149. Bereavement and HIV infection
150. Repeated bereavement, depressed mood, and immune parameters in HIV seropositive and seronegative gay men
151. Depressed lymphocyte function after bereavement
152. Impaired natural killer cell activity during bereavement
153. Bereavement is associated with time-dependent decrements in cellular immune function in asymptomatic human immunodeficiency virus type 1-seropositive homosexual men
154. Group intervention to improve coping with AIDS-related bereavement: Model development and an illustrative clinical example
155. A randomized controlled clinical trial of a bereavement support group intervention in human immunodeficiency virus type 1-seropositive and -seronegative homosexual men
156. Personality disorder in HIV infection
157. Axis II diagnoses among volunteers for HIV testing and counseling
158. Psychiatric care for patients with HIV infection: The varying perspectives
159. Personality disorder in patients infected with HIV: A controlled study with implications for clinical care
160. Axis I psychiatric symptoms associated with HIV infection and personality disorder
161. Intravenous drug abusers with antisocial personality disorder: Increased HIV risk behavior
162. Personality disorders predict onset of axis I disorders and impaired functioning among homosexual men with and at risk of HIV infection
163. Life stressors and coping style are associated with immune measures in HIV-1 infection - A preliminary report
164. Psychoneuroimmunology and human immunodeficiency virus type 1 infection revisited
165. Immune system changes after the death of a partner in HIV-positive gay men
166. Stress-associated reductions of cytotoxic T lymphocytes and natural killer cells in asymptomatic HIV infection
167. Severe stress, depressive symptoms, and changes in lymphocyte subsets in human immunodeficiency virus-infected men. A 2-year follow-up study
168. Progression to AIDS: The effects of stress, depressive symptoms, and social support
169. Depression, distress, lymphocyte subsets, and human immunodeficiency virus symptoms on two occasions in HIV-positive homosexual men
170. Stress and HIV infection
171. Depressive symptoms and CD4 lymphocyte decline among HIV-infected men
172. Depressive symptoms as predictors of medical outcomes in HIV infection: Multicenter AIDS Cohort Study
173. Cognitive-behavioral stress management intervention buffers distress responses and immunologic changes following notification of HIV-1 seropositivity
174. A bereavement support group intervention is longitudinally associated with salutary effects on the CD4 cell count and number of physician visits
175. Effect of imipramine on mood and enumerative measures of immune status in depressed patients with HIV illness
176. Unconventional medicine in the United States: Prevalence, costs, and patterns of use
177. Trends in alternative medicine use in the United States, 1990-1997: Results of a follow-up national survey
178. Patterns of use, expenditures, and perceived efficacy of complementary and alternative therapies in HIV-infected patients
179. Determinants of complementary therapy use in HIV-infected individuals receiving antiretroviral or anti-opportunistic agents
180. Determinants of nontraditional therapy use in patients with HIV infection: A prospective study
181. Patient use and assessment of conventional and alternative therapies for HIV infection and AIDS
182. Treatment of human immunodeficiency virus-positive patients with complementary and alternative medicine: A survey of practitioners
183. Complementary and alternative medicine and HIV/AIDS, part II: Selected literature review
184. Most frequently used alternative and complementary therapies and activities by participants in the AMCOA Study
185. A scientific plan for the evaluation of alternative medicine in the treatment of HIV/AIDS
186. A seroprevalence survey for human immunodeficiency virus antibody in mentally retarded adults
187. Human immunodeficiency virus type-1 antibody in 6,703 institutionalized mentally retarded clients: An unlinked serosurvey at seven California developmental centers
188. Predictors of HIV infection among newly sentenced male prisoners
189. Voluntary testing for human immunodeficiency virus (HIV) in a prison population with a high prevalence of HIV
190. HIV infection among women entering the New York State correctional system
191. Collaborative research to prevent HIV among male prison inmates and their female partners
192. Psychosocial impact of HIV-related caregiving on health providers: A review and recommendations for the role of psychiatry
193. Mental health care providers working with HIV: Avoiding stress and burnout
194. The psychological impact on staff of caring for people with serious diseases - The case of HIV infection and oncology
195. The impact of working with people with HIV/AIDS: A review of the literature
196. Support groups for medical caregivers of people with HIV diseases
197. Training programs for staff
198. Emotional reactions of haemophilia health care providers
199. Psychiatric patients and HIV
200. Awkward moments in patient-physician communication about HIV risk
201. Multistate evaluation of anonymous HIV testing and access to medical care
202. Effect of HIV reporting by name on use of HIV testing in publicly funded counseling and testing programs
203. Name-based surveillance and public health interventions for persons with HIV infection
204. Home sample collection tests for HIV infection
205. Strategies for modifying sexual behavior for primary and secondary prevention of HIV disease
206. Developing community networks to deliver HIV prevention interventions
207. Evidence for the effects of HIV antibody counseling and testing on risk behaviors
208. The effects of HIV counseling and testing on risk-related practices and help-seeking behavior
209. Effects of HIV counseling and testing on sexual risk behavior: A meta-analytic review of published research, 1985-1997
210. Stages of change in the modification of problem behaviors
211. Changing AIDS-risk behavior
212. Efficacy of behavioral-skills enhancement HIV risk-reduction interventions in community settings
213. The NIMH Multisite HIV Prevention Trial: Reducing HIV sexual risk behavior
214. Efficacy of risk-reduction counseling to prevent human immunodeficiency virus and sexually transmitted diseases: A randomized controlled trial
215. Reduction in risk behavior among adults with severe mental illness who learned to advocate for HIV prevention
216. An ethnographic comparison of HIV risk behaviors among heroin and methamphetamine injectors
217. HIV epidemiology and interventions among injecting drug users
218. Outreach-based HIV prevention for injecting drug users: A review of published outcome data
219. Needle-exchange attendance and health care utilization promote entry into detoxification
220. The role of needle exchange programs in HIV prevention
221. Effectiveness of needle-exchange programmes for prevention of HIV infection
222. Trends in perinatal transmission of HIV/AIDS in the United States
223. Elective cesarean delivery to reduce the transmission of HIV
224. AIDS among children - United States, 1996
225. Randomized study of the tolerance and efficacy of high-versus low-dose zidovudine in human immunodeficiency virus-infected children with mild to moderate symptoms
226. Risk factors for perinatal transmission of human immunodeficiency virus type 1 in women treated with zidovudine
227. Maternal levels of plasma human immunodeficiency virus type I RNA and the risk of perinatal transmission
228. Developmental pharmacology and toxicology of anti-HIV therapeutic agents: Dideonucleosides
229. Administration of zidovudine during late pregnancy, transmission - Thailand, 1996-1998
230. Reduction of mother-child transmission of HIV infection in Africa: From clinical research to public health programs
231. Public Health Service Task Force recommendations for the use of antiretroviral drugs in pregnant women infected with HIV for maternal health and for reducing perinatal HIV-1 transmission in the United States
232. Antiretroviral therapies in pregnancy: Maternal, fetal and neonatal effects: Swiss HIV Cohort Study, the Swiss Collaborative HIV and Pregnancy Study, and the Swiss Neonatal HIV Study
233. Occupational risk of human immunodeficiency virus infection in healthcare workers: An overview
234. A case-control study of HIV seroconversion in health care workers after percutaneous exposure
235. Effectiveness of an HIV risk reduction counseling intervention for out-of-treatment drug users
236. Mental disorder as a risk factor for human immunodeficiency virus infection in a sample of veterans
237. HIV prevention in prisons and jails: Obstacles and opportunities
238. HIV risk reduction and service delivery strategies in criminal justice settings
239. AIDS knowledge and high risk behaviors in the chronic mentally ill
240. Risk for human immunodeficiency virus (HIV) infection among persons with severe mental illnesses
241. Use of a brief behavioral skills intervention to prevent HIV infection among chronic mentally ill adults
242. Effects of AIDS counseling and risk reduction training on the chronic mentally ill
243. Sexual violence against women living with or at risk for HIV infection
244. Childhood sexual abuse among homosexual men: Prevalence and association with unsafe sex
245. The relationship of sexual abuse and HIV risk behaviors among heterosexual adult female STD patients
246. Sexual coercion, domestic violence, and negotiating condom use among low-income African American women
247. Sexual abuse of children: Intersection with the HIV epidemic
248. Influence of sexual abuse on HIV-related attitudes and behaviors in adolescent psychiatric inpatients
249. Correlates of medical service utilization among people with HIV infection
250. AIDS mortality rates lower at sites with HIV experience
251. Race, sex, drug use, and progression of human immunodeficiency virus disease
252. Variations in the care of HIV-infected adults in the United States: Results from the HIV Cost and Services Utilization Study
253. Factors associated with severity of depression and high-risk sexual behavior among persons diagnosed with human immunodeficiency virus (HIV)infection
254. On-site primary care and mental health services in outpatient drug abuse treatment units
255. Delivering mental health care to HIV-positive individuals: A comparison of two models
256. Use of psychotropic drugs in patients with HIV infection
257. The potential impact of efavirenz on methadone maintenance
258. Single-dose pharmacokinetics of delavirdine mesylate and didanosine in patients with human immunodeficiency virus infection
259. Effect of ritonavir on the pharmacokinetics of desipramine
260. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: Relation to drug interactions in vivo
261. Saquinavir interaction with midazolam; pharmacokinetic considerations when prescribing protease inhibitors for patients with HIV disease
262. Fatal interaction between ritonavir and MDMA
263. Depression in the context of human immunodeficiency virus infection: Implications for treatment
264. Selective serotonin reuptake inhibitor treatment of depression in symptomatic HIV infection and AIDS
265. A comparative analysis of standard and alternative antidepressants in the treatment of human immunodeficiency virus patients
266. Randomized, placebo-controlled trial of paroxetine versus imipramine in depressed HIV-positive outpatients
267. Antidepressant efficacy in HIV-seropositive outpatients with major depressive disorder: An open trial of nefazodone
268. Fluoxetine treatment for depression in patients with HIV and AIDS: A randomized, placebo-controlled trial
269. Treatment of major depression in HIV-seropositive men
270. Predominantly sensory neuropathy in patients with AIDS and AIDS-related complex
271. Psychopharmacology in HIV-positive patients: Research perspectives
272. Effects of fluoxetine on mood and immune status in depressed patients with HIV illness
273. Double-blind comparison of fluoxetine and desipramine in the treatment of depressed women with advanced HIV disease: A pilot study
274. Notes on the use of fluvoxamine as treatment of depression in HIV-1 infected subjects
275. Rational psychopharmacology in patients with HIV infection and AIDS
276. Venlafaxine and indinavir: Results of a pharmacokinetic interaction study
277. Atypical antipsychotic drugs in the treatment of manic syndromes in patients with HIV-1 infection
278. Extrapyramidal symptoms due to dopamine-blocking agents in patients with AIDS encephalopathy
279. AIDS and neuroleptic malignant syndrome
280. HIV and acute onset of psychosis
281. Severe parkinsonism in two AIDS patients taking prochlorperazine
282. Excitotoxicity and dopaminergic dysfunction in the acquired immunodeficiency syndrome dementia complex
283. Extrapyramidal reactions: Neuropsychiatric mimics in patients with AIDS
284. Extrapyramidal symptoms in AIDS patients given low-dose metoclopramide or chlorpromazine
285. HIV infection presenting as psychosis: A critique
286. A prospective analysis of 24 episodes of neuroleptic malignant syndrome
287. AIDS presenting as mania
288. Adverse neuropsychiatric effects of dopamine antagonist medications: Misdiagnosis in the medical setting
289. Risperidone for AIDS-associated dementia - A case series
290. Rapidly progressive tardive dyskinesia in AIDS
291. The use of molindone in the treatment of psychotic and delirious patients infected with the human immunodeficiency virus: Case reports
292. Persistent neuroleptic-induced rigidity and dystonia in AIDS dementia complex: A clinico-pathological case report
293. HIV and onset of schizophrenia
294. Treatment of HIV-related psychotic disorders with risperidone: A series of 21 cases
295. Movement disorders and AIDS
296. A randomized trial of amitriptyline and mexiletine for painful neuropathy in HIV infection
297. Nomenclature and research case definitions for neurologic manifestations of human immunodeficiency virus-type 1 (HIV-1) infection
298. Relation between elderly and AIDS patients with drug-induced Parkinson's disease
299. Pilot study with clozapine in patients with HIV-associated psychosis and drug-induced parkinsonism
300. Response of HIV-related depression to psychostimulants: Case reports
301. Dextroamphetamine as a treatment for depression and low energy in AIDS patients: A pilot study
302. Does valproate pose a threat to human immunodeficiency virus-infected patients?
303. The effect of divalproex sodium on viral load: A retrospective review of HIV-positive patients with manic syndromes
304. Hepatotoxicity with combination of valproic acid, ritonavir and nevirapine: A case report
305. Possible risks associated with valproate treatment of AIDS-related mania
306. Effect of lithium carbonate in HIV-infected patients with immune dysfunction
307. Buspirone in drug users with AIDS or AIDS-related complex
308. Buspirone-induced psychosis in a human immunodeficiency virus-infected man
309. Effect of ritonavir on the pharmacokinetics and pharmacodynamics of alprazolam
310. Alprazolamritonavir interaction: Implications for product labeling
311. Pharmacokinetics of protease inhibitors and drug interactions with psychoactive drugs
312. The effects of oxandrolone on body weight and composition in patients with HIV-associated weight loss
313. Effects of oxandrolone on body weight and composition in patients with HIV-associated weight loss
314. Oxandrolone as a treatment for AIDS-related weight loss and wasting
315. The effects of chronic growth hormone therapy on dietary intake in patients with HIV-associated weight loss
316. Growth hormone in the treatment of weight loss AIDS-related
317. Short and long time treatment with growth hormone in AIDS wasting syndrome increase in quality of life and nutritional status
318. A phase III study of recombinant human growth hormone (mammalian cell-derived) in patients with AIDS wasting
319. A randomized, double-blind, placebo-controlled phase 11 trial of growth hormone and insulin-like growth factor I for AIDS wasting
320. Thalidomide associated weight gain in HIV-1 positive clients
321. Effects of thalidomide on HIV-associated wasting syndrome: A randomized, double-blind, placebo controlled clinical trial
322. Testosterone replacement therapy in HIV illness
323. Testosterone replacement options for HIV-infected men
324. The physiologic and pharmacological roles of cytochrome P450 enzymes
325. Pharmacokinetic interactions of zidovudine and methadone in intravenous drug-using patients with HIV infection
326. Clinical problems associated with interactions between methadone pharmacotherapy and medications used in the treatment of HIV-1 positive and AIDS patients
327. Methadone effects on zidovudine disposition
328. Opioid effects on zidovudine disposition
329. The pharmacokinetics (PK) of abacavir (ABC) and methadone (M) following coadministration: CNAAL 01 2
330. In vitro effect of HIV protease inhibitors on methadone metabolism
331. Decrease in methadone levels with nelfinavir mesylate
332. Nevirapine induced opiate withdrawal among injection drug users with HIV infection receiving methadone
333. Indinavir concentrations and St John's wort
334. Resilience factors associated with adaptation to HIV disease
335. Assessment and psychotherapy pracrice implications of new combination antiviral therapies in HIV disease
336. From fate to tragedy: The changing meanings of life, death, and AIDS
337. Psychosocial factors associated with risky sexual behavior among HIV-seropositive gay men
338. Psychosocial aspects of antiretroviral medication use among HIV patients
339. Missed opportunities? Disclosure of HIV and support seeking among HIV positive African-American and European-American men
340. Psychological sequelae of HIV infection and AIDS: Review of empirical findings
341. HIV-illness, social support, sense of coherence, and psychosocial
342. The relationship between social support and health in gay men with HIV/AIDS: An integrative review
343. Coping with the threat of AIDS: The role of social support
344. HIV infection and AIDS in the public health and health care systems: The role of law and litigation
345. The outreach-assisted model of partner notification with IDUS
346. Partner notification for HIV prevention: A critical reexamination
347. HIV partner notification - Taking a new look
348. AIDS policy: Position statement on confidentiality, disclosure, and protection of others
349. The Academy of Psychosomatic Medicine practice guidelines for psychiatric consultation in the general medical setting
350. Protease inhibitors and the new AIDS combination therapies: Implication for psychological services
351. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions
352. Adherence to treatment
353. HIV Neurocognitive disorders
354. Adherence in AIDS clinical trials: A framework for clinical research and clinical care
355. Adherence to zidovudine (AZT) among HIV-infected methadone patients: A pilot study of supervised therapy and dispensing compared to usual care
356. Medication adherence strategies for drug abusers with HIV/AIDS
357. Cerebrospinal-fluid HIV-1 RNA and drug concentrations after treatment with lamivudine plus zidovudine or stavudine
358. Effect of antiretroviral therapy on the cerebrospinal fluid of patients seropositive for the human immunodeficiency virus
359. Subtle neuropsychological impairment and minor cognitive-motor disorder in HIV-1 infection: Neuroradiological, neurophysiological, neuroimmunological, and virological correlates
360. Zidovudine treatment of the AIDS dementia complex: Results of a placebo-controlled trial
361. Neuropsychological outcome of zidovudine (AZT) treatment of patients with AIDS and AIDS-related complex
362. Evaluation of neuro psychiatric parameters in HIV positive subjects treated with zidovudine
363. Reduced frequency of HIV-induced brain lesions in AIDS patients treated with zidovudine
364. Influence of risk group and zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients
365. Cerebrospinal fluid beta 2-microglobulin in patients with AIDS dementia complex: An expanded series including response to zidovudine treatment
366. The effect of zidovudine on neuropsychiatric measures in HIV-infected men
367. Transmission of antiretroviral-drug-resistant HIV-1 variants
368. Neurocognitive effects of zidovudine and 2',3'-dideoxyinosine during the treatment of asymptomatic and symptomatic HIV1 seropositive patients; comparison with non-treated patients
369. Safety and efficacy of abacavir (ABC, 1592) in AIDS dementia complex (study CNAB 3001)
370. The transport of the anti-HIV drug, 2',3'didehydro-3'-deoxythymidine (D4T), across the blood-brainand blood-cerebrospinal fluid barriers
371. Indinavir in cerebrospinal fluid of HIV-1-infected patients
372. Highly active antiretroviral treatment in HIV infection: Benefits for neuropsychological function
373. Natural history of advanced HIV disease in patients treated with zidovudine
374. Italian multicenter study of didanosine: Compassionate use in advanced HIV infection
375. Incidence of AIDS dementia in a two-year follow-u p of AlDS and ARC patients on an initial phase II AZT placebo-controlled study: San Diego cohort
376. Randomized doubleblind placebo-controlled trial of peptide T for HIV-associated cognitive impairment
377. HIV-related neurona injury: Potential therapeutic intervention with calcium channel antagonists and NMDA antagonists
378. Neuropsychological effects of interferon alfa-n3 treatment in asymptomatic human immunodeficiency virus-1-infected individuals
379. Phase I trial of interferon alfa-n3 n early-stage human immunodeficiency virus type I disease: Evidence for drugsafety, tolerance, and antiviral activity
380. Nimodipine plus zidovudine versus zidovudine alone in the treatment of HIV-1-associated cognitive deficits
381. A phase 1/11 trial of nimodi pine for HIV-related neurologic complications
382. Sustained-release methylphenidate for cognitive impairment in HIV-1-infected drug abusers: A pilot study
383. Psychostimulant response in AIDS-related complex patients
384. Dana Consortium on the Therapy of HIV Dementia and Related Cognitive Disorders: A randomized, double-blind, placebo-controlled trial of deprenyl and thioctic acid in human immunodeficiency virus-associated cognitive impairment
385. Tryptophan concentrations increase in cerebrospinal fluid and blood alter zidovudine treatment in patients with HIV type I infection
386. Reversal of apparent AIDS dementia corn plex following treatment with vitamin B12
387. Emergency pharmacotherapy in the critically ill cancer patient
388. A 'new' drug for treating agitation and psychosis in the general hospital: Chlorpromazine
389. A symptom rating scale for delirium
390. Droperidol vs haloperidol in the initial management of acutely agitated patients
391. Droperidol versus haloperidol for chemical restraint of agitated and combative patients
392. Ethnic differencesin response to fluoxetine in a controlled trial with depressed HIV-positive patients
393. Treatment of depression in HIV-infected patients
394. A report of eight HIV-seropositive patients with major de pression responding to fluoxetine
395. Efficacy of paroxetine for the treatment of depression in the context of HIV infection
396. Antidepressant treatment of depression in HIV-seropositive women
397. Efficacy of venlafaxine in HIV-depressive disorders
398. Methylphenidate as a treatment for depression in acquired immunodeficiency syndrome: An n-of-1 trial
399. The use of methylphenidate in a depressed adolescent with AIDS
400. HIV-related major depression: Response to zidovudine treatment
401. ECT for major depression in four patients infected with human immunodeficiency
402. Structured group therapy and fluoxetine to treat depression in HIV-positive persons
403. Treatment of depressive symptoms in human immunodeficiency virus-positive patients
404. Interpersonal psychotherapy of depressed HIV-positive outpatients
405. Group psychotherapy for HIV-seropositive patients with major depression
406. The effectiveness of psychiatric treatment for HIV-infected patients
407. Outcome of cognitive-behavioral and support group brief therapies for depressed, HIV-infected persons
408. Effects of two cognitive-behavioral interventions on immunity and symptoms in persons with HIV
409. Anticonvulsant use in the treatment of manic syndromes in patients with HIV-1 infection
410. Valproicacid treatment of AIDS-related mania
411. Evaluation of a hospital based substance abuse intervention and referral service for HIV affected patients
412. Methadone maintenance program for AIDS-affected opiate addicts
413. HIV-infected intravenousdrug users in methadone maintenance treatment: Clinical problems and their management
414. Influence of a methadone maintanance programme on the improved outcome of a cohort of injecting drug users with advanced HIV disease
415. Diagnosis and management of HIV-related mood and anxiety disorders
416. Obsessive-compulsive disorder in HIV disease: Response to fluoxetine
417. Trichotillomania associated with HtV infection in response to sertraline
418. Diagnosis and clinical use of bromperidol in HIV-related psychoses in a sample of seropositive patients with brain damage
419. AIDS-related psychosis with catatonia responding to low-dose Iorazepam
420. Catatonia in a patient with AIDS-related dementia
421. AIDS dementia-related psychosis: Is there a window of vulnerability?
422. Sleep disturbances in HIV-infected homosexual men
423. Sleep disturbances in men with asymptomatic human immunodeficiency (HIV) infection
424. Fatigue, sleep disturbance, disability, and indices of progression of HIV infection
425. Growth hormone fatigue,poor sleep, and disability in HIV infection
426. Obstructive sleep apnea in patients with human immunodeficiency virus (HIV) disease
427. The effects of flurazepam on sleep in AIDS patients
428. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection
429. Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection
430. A 12-month study of the effects of oral zidovudine on neurodevelopmental functioning in a cohort of vertically HIV-infected inner-city children
431. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens
432. Neurodevelopmental/neuroradiologic recovery of a child infected with HIV after treatment with combination antiretroviral therapy using the HIV-specific protease inhibitor ritonavir
433. Case study: Behavioral symptoms of pediatric HIV-1 encephalopathy successfully treated with clonidine
434. Management of recalcitrant pain in a pediatric acquired immunodeficiency syndrome patient
435. Pain in pediatric human immunodeficiency virus infection: Incidence and characteristics in a single-institution pilot study, Pediatrics
436. Effects of androgen administration in men with the AIDS wasting syndrome: A randomized, double-blind, placebo-controlled trial
437. Testosterone treatment of clinical hypogonadism in patients with HIV/AIDS
438. Oxymetholone promotes weight gain in patients with advanced human immunodeficiency virus (HIV-1) infection
439. Transdermal testosterone administration in women with acquired immunodeficiency syndrome wasting: A pilot study
440. Exercise as a mediator of psychological and nutritional effects of testosterone therapy in HIV+ men
441. Resistance exercise and supraphysiologic androgen therapy in eugonadal men with HIV-related weight loss: A randomized controlled trial
442. Psychostimulants for fatigue in the HIV+ patient: Preliminary findings of a placebo-controlled trial of methylphenidate vs pemoline
443. DHEA treatment for HIV+ patients: Effects on mood, androgenic and anabolic parameters
444. Assessing and managing pain in AIDS care: The patient perspective
445. Mexiletine for HIV-infected patients with painful peripheral neuropathy: A double-blind, placebo-controlled, crossover treatment trial
446. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized controlled trial: Terry Beirn Community Programs for Clinical Research on AIDS
447. Interaction between sildenafil and HIV-1 combination therapy